Baizensel Establishes Australian Corporation... "First Foothold for Global Expansion"

[Asia Economy Reporter Lee Gwan-joo] ViGenCell, a company developing immune cell therapies, announced on the 29th that it will enter overseas markets with the establishment of its local Australian subsidiary, 'ViGenCell Australia Pty Ltd.'

Australia has well-established clinical infrastructure that allows for rapid clinical entry, and the company believes it offers various advantages, including the ability to utilize clinical results when obtaining approvals from agencies such as the U.S. Food and Drug Administration (FDA) in the future.

Through the establishment of the Australian subsidiary, ViGenCell will focus on global clinical trials and license-outs (L/O) of its universal therapeutic platforms, ViMedier™ and ViRanger™. After setting up the Australian subsidiary, the company plans to apply for overseas clinical trial plans (IND) in the fourth quarter.

The first clinical trial to be conducted by the Australian subsidiary will be ViMedier. The pipeline ‘VM-AD,’ targeting severe atopic dermatitis, demonstrated significant efficacy in preclinical animal model experiments and is scheduled for an oral presentation at the American Association of Immunologists (AAI) in May.

Kim Tae-gyu, CEO of ViGenCell, said, “The establishment of the Australian subsidiary offers various advantages in terms of clinical progress and benefits, making it the first foothold for global expansion. Through the establishment of the Australian subsidiary, we will realize overseas clinical plans one by one and gradually expand our presence in the global market.”

This content was produced with the assistance of AI translation services.